BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biotechnology company, announced a significant financial and strategic transaction involving…
Quanterix Accelerator Laboratory Secures New York State Clinical Laboratory Permit, Expanding Biomarker Research and Clinical Testing Capabilities Nationwide Quanterix Corporation (NASDAQ: QTRX), a biotechnology company recognized for revolutionizing precision medicine through its ultrasensitive biomarker detection platforms, today announced a major…
Altasciences Chosen by Steel Therapeutics to Advance Pivotal Toxicology Study for Fizurex™ Altasciences, a leading provider of integrated drug development solutions, announced that it has been selected by Steel Therapeutics, Inc. (“Steel”) to initiate a pivotal toxicology study for Fizurex™,…
PureTech Showcases Differentiated IPF Strategy, Highlights Patient Insights, and Positions Deupirfenidone as a Potential New Standard of Care PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company devoted to transforming outcomes for patients facing devastating diseases, took center…
Circle Pharma’s Nature Publication Highlights Breakthrough in Cyclin A/B RxL Inhibition and Preclinical Anti-Tumor Activity Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, announced the publication of a landmark paper in Nature detailing…
Nuvem Expands Leadership Team to Accelerate Pharmacy Service Model for Community Health Providers Strengthened product, technology, and finance leadership positions company to scale mission-driven pharmacy solutions Nuvem, a leading tech-enabled pharmacy services company dedicated to empowering community health providers, today…
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Lead the Next Era of Radiopharmaceutical Innovation Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) focused exclusively on radiopharmaceuticals, has appointed Dr. Stephen M. Hahn as…
MedImpact Unveils Affordable Access to Unbranded Ustekinumab-aekn Biosimilar, Reshaping Specialty Pharmacy Market MedImpact Holdings Inc., the nation’s largest independent pharmacy benefit and healthcare solutions provider, announced a major step toward addressing escalating specialty drug costs with the launch of access…
ConcertAI Appoints Michael Myshrall as Chief Financial Officer, Strengthening Financial Leadership to Drive Growth in AI-Powered Healthcare and Life Sciences ConcertAI, a global leader in oncology generative and agentic artificial intelligence (AI) software-as-a-service (SaaS) and multi-modal data (MMD) solutions for…
RenovoRx Reports Strong Q2 2025 Revenue Growth and Receives Positive Independent Committee Recommendation to Continue Phase III TIGeR-PaC Trial RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage life sciences company pioneering targeted oncology drug delivery therapies, announced financial results for the second…
Scholar Rock Announces Landmark Lancet Neurology Publication of Pivotal Phase 3 SAPPHIRE Trial Results for Apitegromab in Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to advancing innovative treatments for serious neuromuscular diseases, announced today that…
Alto Neuroscience Appoints Raymond Sanchez, M.D., to Board of Directors, Strengthening Leadership as Company Advances Late-Stage Precision Psychiatry Pipeline Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company pioneering the development of novel precision medicines for neuropsychiatric disorders, today…